NuCana PLC Sponsored ADR (NASDAQ:NCNA) – Analysts at William Blair issued their Q3 2017 earnings estimates for shares of NuCana PLC Sponsored ADR in a research report issued on Monday. William Blair analyst Y. Xu expects that the company will post earnings of ($0.09) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for NuCana PLC Sponsored ADR’s Q4 2017 earnings at ($0.11) EPS, FY2017 earnings at ($0.34) EPS and FY2018 earnings at ($0.62) EPS.

A number of other equities analysts have also weighed in on NCNA. Jefferies Group LLC started coverage on NuCana PLC Sponsored ADR in a research report on Monday. They issued a “buy” rating and a $25.00 target price for the company. Cowen and Company started coverage on NuCana PLC Sponsored ADR in a research report on Monday. They issued an “outperform” rating for the company. Finally, Citigroup Inc. started coverage on NuCana PLC Sponsored ADR in a research report on Monday. They issued a “buy” rating and a $23.00 target price for the company.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/25/equities-analysts-offer-predictions-for-nucana-plc-sponsored-adrs-q3-2017-earnings-ncna.html.

NuCana PLC Sponsored ADR (NASDAQ:NCNA) opened at 13.80 on Wednesday. The company’s 50-day moving average is $15.83 and its 200 day moving average is $15.83. NuCana PLC Sponsored ADR has a 52-week low of $13.05 and a 52-week high of $19.95. The company’s market cap is $438.99 million.

About NuCana PLC Sponsored ADR

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Earnings History and Estimates for NuCana PLC Sponsored ADR (NASDAQ:NCNA)

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.